Barclays’s Agios Pharmaceuticals AGIO Stock Holding History

Barclays’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-52,200	Closed	-$1.42M	–	5010
2025 Q4	$1.42M	Buy	+52,200	New	+$1.83M	﹤0.01%	3184
2024 Q4	–	Sell	-32,200	Closed	-$1.43M	–	5251
2024 Q3	$1.43M	Hold	32,200	–	–	﹤0.01%	3116
2024 Q2	$1.39M	Buy	32,200 +2,200	+7%	+$79.4K	﹤0.01%	2391
2024 Q1	$877K	Sell	30,000 -30,000	-50%	-$803K	﹤0.01%	3222
2023 Q4	$1.34M	Buy	+60,000	New	+$1.34M	﹤0.01%	3226
2019 Q3	–	Sell	-300	Closed	-$15K	–	6667
2019 Q2	$15K	Hold	300	–	–	﹤0.01%	6471
2019 Q1	$20K	Sell	300 -147,500	-100%	-$8.59M	﹤0.01%	6352
2018 Q4	$6.82M	Buy	+147,800	New	+$9.12M	0.01%	1393
2018 Q3	–	Sell	-27,000	Closed	-$2.27M	–	7085
2018 Q2	$2.27M	Hold	27,000	–	–	﹤0.01%	2465
2018 Q1	$2.21M	Buy	+27,000	New	+$2.09M	﹤0.01%	2366
2015 Q1	–	Sell	-25,800	Closed	-$2.89M	–	7047
2014 Q4	$2.89M	Buy	+25,800	New	+$2.3M	﹤0.01%	2192

Other funds holding AGIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Barclays's AGIO Position: Q2 2026 in Review

Barclays reduced its Agios Pharmaceuticals (AGIO) stake by 7.9% in Q2 2026, selling an estimated $126K and leaving 48,300 shares worth $1.79M. The position accounts for ﹤0.01% of the portfolio, ranked #2410.

Barclays first reported a position in AGIO in Q3 2013 and has held it in 52 quarters since. The position peaked at $8.72M in Q4 2025. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

Barclays held 48,300 shares of Agios Pharmaceuticals worth $1.79M as of Q2 2026.
Barclays sold 4,138 Agios Pharmaceuticals shares in Q2 2026, an estimated $126K.
Agios Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2410 holding.
Barclays first reported a position in Agios Pharmaceuticals in Q3 2013 and has held it in 52 quarters since.
Barclays's Agios Pharmaceuticals position peaked at $8.72M in Q4 2025.
238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.